With a robust pipeline and strategic focus on research and development, Amgen is positioning itself for potential growth while facing challenges in a rapidly evolving industry. According to ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

Amgen’s strong commitment to R&D, coupled with its successful integration of strategic acquisitions like Horizon Therapeutics (NASDAQ:HZNP), demonstrates the company’s ability to drive innovation and ...

Management emphasized its commitment to driving pipeline development, especially in emerging therapeutic areas like oncology and rare diseases. Updates on MariTide, Amgen's weight-reduction ...

Strategic acquisitions and pipeline expansions remain central to future growth plans. Amgen revealed a positive third quarter of 2024, exceeding earnings expectations. Despite some challenges in ...

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...

If Amgen can successfully bring these pipeline assets to market, it could offset potential losses from patent expirations and drive sustained long-term growth. This analysis is based on ...